Lupin receives approval from US FDA for Arformoterol Tartrate inhalation solution

Lupin yesterday announced that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Arformoterol Tartrate inhalation solution 15 mcg (base)/2 ml, unit-dose Vialsto market, a generic equivalent of Brovana inhalation solution, 15 mcg/2 ml of Sunovion Pharmaceuticals Inc, Lupin notified in a statement.

Arformoterol Tartrate inhalation solution 15 mcg (base)/2 ml, unit-dose vials are indicated for the long-term maintenance treatment of bronchoconstriction in patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema. Arformoterol Tartrate inhalation solution is for use by nebulisation only, added the statement.